Broadening our impact
DLL3
Our lead program targets DLL3, a cell-surface protein widely expressed across a range of cancers, with limited expression on healthy cells. This selective expression makes DLL3 an ideal target for treating these aggressive cancers, which today have poor survival rates.
This program is currently being evaluated in a Phase 1 clinical trial in advanced DLL3-expressing tumors. Visit clinicaltrials.gov to learn more about the study (NCT07006727).
B7-H3
Our second program targets B7-H3, which is highly expressed across many types of cancer and correlates with poor patient survival and prognosis. B7-H3 has been shown to promote tumor cell proliferation and metastases and help tumor cells evade the immune system.
Discovery programs
Our selection of novel targets and innovative approach to designing compounds and radioligand therapies fuel a robust portfolio of early-stage programs, each with the potential to address a broad range of cancers. Lead candidates are engineered for selective target binding, tumor penetration, and rapid clearance of unbound molecules for treatments with high impact on tumors and minimal unwanted side effects.
